Lates News

AstraZeneca announces that the long-acting C5 complement inhibitor Ultomiris (generic name: ravulizumab injection) has been officially launched in China for use in combination with conventional treatment drugs for the treatment of adult generalized myasthenia gravis (gMG) patients who are positive for anti-acetylcholine receptor (AChR) antibodies, as well as for the treatment of adult neuromyelitis optica spectrum disorder (NMOSD) patients who are positive for anti-aquaporin-4 (AQP4) antibodies.